oa SA Pharmaceutical Journal - Atopic eczema : current therapeutic advances : clinical

Volume 73, Issue 9
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Atopic eczema significantly affects the quality of life of sufferers. <br>There are good epidemiological data supporting the view that the prevalence is on the rise. The reasons for this are not clear. <br>A single treatment modality is not sufficient in controlling the disease. <br>The availability of new classes of drugs such as calcineurin inhibitors is a significant advance in the management of atopic eczema. <br>The calcineurin inhibitors can be used as first-line therapy for atopic eczema. <br>A comprehensive approach is required encompassing allergen avoidance, use of moisturisers, careful application of topical steroids and use of the recently available topical calcineurin inhibitors. <br>Most patients can be well controlled with a combination of these treatments.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error